5.67
+0(+0.00%)
Currency In USD
| Previous Close | 5.67 |
| Open | 5.67 |
| Day High | 5.67 |
| Day Low | 5.67 |
| 52-Week High | 6.28 |
| 52-Week Low | 1.94 |
| Volume | 10.9M |
| Average Volume | 1.45M |
| Market Cap | 302.2M |
| PE | -3.13 |
| EPS | -1.81 |
| Moving Average 50 Days | 5.34 |
| Moving Average 200 Days | 3.86 |
| Change | 0 |
If you invested $1000 in scPharmaceuticals Inc. (SCPH) since IPO date, it would be worth $402.13 as of December 04, 2025 at a share price of $5.67. Whereas If you bought $1000 worth of scPharmaceuticals Inc. (SCPH) shares 5 years ago, it would be worth $648.74 as of December 04, 2025 at a share price of $5.67.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Data not available
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
GlobeNewswire Inc.
Oct 07, 2025 1:02 PM GMT
DANBURY, Conn. and BURLINGTON, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced acquisition of scPharmaceuticals Inc. The acquisition of scPharmaceuticals is expected to di
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
GlobeNewswire Inc.
Aug 25, 2025 11:31 AM GMT
Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet needUpfront cash payment of $5.35 per
scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111
GlobeNewswire Inc.
Aug 14, 2025 12:30 PM GMT
BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, announced today that it ha